Qin Zhiyuan, Xu Qingwen, Hu Haihong, Yu Lushan, Zeng Su
College of Pharmaceutical Sciences, Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang University, Hangzhou, China.
Front Oncol. 2020 May 7;10:724. doi: 10.3389/fonc.2020.00724. eCollection 2020.
Renal cell carcinoma (RCC) is the most common type of kidney cancer. Increasingly evidences indicate that extracellular vesicles (EVs) orchestrate multiple processes in tumorigenesis, metastasis, immune evasion, and drug response of RCC. EVs are lipid membrane-bound vesicles in nanometer size and secreted by almost all cell types into the extracellular milieu. A myriad of bioactive molecules such as RNA, DNA, protein, and lipid are able to be delivered via EVs for the intercellular communication. Hence, the abundant content of EVs is appealing reservoir for biomarker identification through computational analysis and experimental validation. EVs with excellent biocompatibility and biodistribution are natural platforms that can be engineered to offer achievable drug delivery strategies for RCC therapies. Moreover, the multifaceted roles of EVs in RCC progression also provide substantial targets and facilitate EVs-based drug discovery, which will be accelerated by using artificial intelligence approaches. In this review, we summarized the vital roles of EVs in occurrence, metastasis, immune evasion, and drug resistance of RCC. Furthermore, we also recapitulated and prospected the EVs-based potential applications in RCC, including biomarker identification, drug vehicle development as well as drug target discovery.
肾细胞癌(RCC)是最常见的肾癌类型。越来越多的证据表明,细胞外囊泡(EVs)在RCC的肿瘤发生、转移、免疫逃逸和药物反应中协调多个过程。EVs是纳米尺寸的脂质膜结合囊泡,几乎所有细胞类型都能将其分泌到细胞外环境中。诸如RNA、DNA、蛋白质和脂质等众多生物活性分子能够通过EVs进行细胞间通讯。因此,EVs丰富的内容物是通过计算分析和实验验证来鉴定生物标志物的理想来源。具有优异生物相容性和生物分布的EVs是天然平台,可进行工程改造以提供可行的RCC治疗药物递送策略。此外,EVs在RCC进展中的多方面作用也提供了大量靶点,并促进基于EVs的药物发现,利用人工智能方法将加速这一进程。在本综述中,我们总结了EVs在RCC发生、转移、免疫逃逸和耐药性中的重要作用。此外,我们还概述并展望了基于EVs在RCC中的潜在应用,包括生物标志物鉴定、药物载体开发以及药物靶点发现。